Refractory Convulsive Status Epilepticus in Children: Etiology, Associated Risk Factors and Outcome

Mohammad Barzegar1, Mohammad Mahdavi2, Afshin Galegolab Behbehani3

  • 1Pediatric Neurology Department Pediatric Health Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.

Insights

Refractory status epilepticus (RSE) in children is often caused by acute symptomatic etiology, such as encephalitis. Early management of these conditions is crucial to prevent mortality and long-term neurological deficits.

Area of Science:

  • Pediatric Neurology
  • Critical Care Medicine
  • Epidemiology

Background:

  • Refractory status epilepticus (RSE) presents a significant threat to children, characterized by seizures unresponsive to initial anticonvulsant therapy.
  • RSE is associated with substantial rates of mortality and long-term morbidity in pediatric populations.

Purpose of the Study:

  • To identify risk factors contributing to the progression from status epilepticus (SE) to RSE in children.
  • To evaluate the early outcomes for pediatric patients diagnosed with RSE.

Main Methods:

  • A retrospective study of pediatric patients with SE hospitalized at Tabriz Children's Hospital between 2007 and 2008.
  • Data collected included clinical profiles, etiology, treatment modalities, and patient outcomes upon discharge.

Main Results:

  • Out of 132 SE patients, 53 (40.15%) had RSE. Acute symptomatic etiology was a significant risk factor for developing RSE (P=0.004), with encephalitis being the most common cause.
  • No significant association was found between RSE and patient age, gender, initial drug intake timing, or seizure type.
  • The mortality rate was 8.3%, and new neurological deficits occurred in 25.7% of cases. Patients with RSE, particularly those with encephalitis, had poorer outcomes compared to non-RSE patients (P=0.006).

Conclusions:

  • The etiology of SE critically impacts prognosis, with a higher incidence of RSE observed in the acute symptomatic group.
  • Prompt and effective management of acute neurological insults like encephalitis and meningitis is essential to mitigate the risk of permanent brain damage in children with SE.
Abstract

Related Concept Videos

Epilepsy and Seizures: Overview01:24

Epilepsy and Seizures: Overview

Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
1.7K
Seizures: Classification01:13

Seizures: Classification

Epilepsy is primarily characterized by unpredictable seizures, either provoked by an identifiable factor, such as injury or illness, or unprovoked, occurring spontaneously without apparent cause.
Seizures are typically classified into two main categories: focal and generalized seizures.
Focal Seizures
Focal seizures originate from specific regions of the brain. These seizures are further sub-classified into two types:
2.2K
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein01:20

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein

Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
1.1K
Antiepileptic Drugs: GABAergic Pathway Potentiators01:18

Antiepileptic Drugs: GABAergic Pathway Potentiators

γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
1.6K
Antiepileptic Drugs: Potassium Channel Activators01:20

Antiepileptic Drugs: Potassium Channel Activators

Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
949
Electroconvulsive Therapy01:30

Electroconvulsive Therapy

Electroconvulsive therapy (ECT), or shock therapy, remains a critical biomedical intervention for severe, treatment-resistant depression. While its origins can be traced back to Hippocrates' observations that malaria-induced convulsions alleviated mental illness, modern ECT has evolved significantly from its earlier, more primitive applications. First introduced in 1938 by Ugo Cerletti and his colleagues, ECT involves inducing controlled seizures using electrical currents. In its early...
2.0K